Review



ic 50 calculation with graphpad prism 7 software  (GraphPad Software Inc)


Bioz Verified Symbol GraphPad Software Inc is a verified supplier  
  • Logo
  • About
  • News
  • Press Release
  • Team
  • Advisors
  • Partners
  • Contact
  • Bioz Stars
  • Bioz vStars
    • 90
      Buy from Supplier

    Structured Review

    GraphPad Software Inc ic 50 calculation with graphpad prism 7 software
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ic 50 Calculation With Graphpad Prism 7 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc11697375-239-3-8?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    ic 50 calculation with graphpad prism 7 software - by Bioz Stars, 2026-06
    90/100 stars

    Images

    1) Product Images from "A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan"

    Article Title: A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan

    Journal: Scientific Reports

    doi: 10.1038/s41598-024-84566-y

    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Figure Legend Snippet: Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.

    Techniques Used: Control, CCK-8 Assay



    Similar Products

    ic 50 calculation with graphpad prism 7 software  (GraphPad Software Inc)
    90
    GraphPad Software Inc ic 50 calculation with graphpad prism 7 software
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ic 50 Calculation With Graphpad Prism 7 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc11697375-239-3-8?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    ic 50 calculation with graphpad prism 7 software - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    ic 50 curve fitting tool of the graphpad prism 10  (GraphPad Software Inc)
    90
    GraphPad Software Inc ic 50 curve fitting tool of the graphpad prism 10
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ic 50 Curve Fitting Tool Of The Graphpad Prism 10, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc11237012-284-23-26?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    ic 50 curve fitting tool of the graphpad prism 10 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    ic 50 logistic equation using graphpad prism v8.3.0  (GraphPad Software Inc)
    90
    GraphPad Software Inc ic 50 logistic equation using graphpad prism v8.3.0
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ic 50 Logistic Equation Using Graphpad Prism V8.3.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc10907753-424-34-33?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    ic 50 logistic equation using graphpad prism v8.3.0 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    variable slope, four parameter ic 50 equation graphpad prism 9.4.0  (GraphPad Software Inc)
    90
    GraphPad Software Inc variable slope, four parameter ic 50 equation graphpad prism 9.4.0
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Variable Slope, Four Parameter Ic 50 Equation Graphpad Prism 9.4.0, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc10604783-130-24-30?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    variable slope, four parameter ic 50 equation graphpad prism 9.4.0 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    ic-50 calculation of graphpad prism  (GraphPad Software Inc)
    90
    GraphPad Software Inc ic-50 calculation of graphpad prism
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ic 50 Calculation Of Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pm37509386-87-11-11?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    ic-50 calculation of graphpad prism - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    cc 50 calculated using graphpad prism software  (GraphPad Software Inc)
    90
    GraphPad Software Inc cc 50 calculated using graphpad prism software
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Cc 50 Calculated Using Graphpad Prism Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc09937549-233-19-23?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    cc 50 calculated using graphpad prism software - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    ec 50 via graphpad prism v7 software  (GraphPad Software Inc)
    90
    GraphPad Software Inc ec 50 via graphpad prism v7 software
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ec 50 Via Graphpad Prism V7 Software, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc07285400-92-13-12?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    ec 50 via graphpad prism v7 software - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    ic 50 of the inhibitory concentration calculated using graphpad prism  (GraphPad Software Inc)
    90
    GraphPad Software Inc ic 50 of the inhibitory concentration calculated using graphpad prism
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Ic 50 Of The Inhibitory Concentration Calculated Using Graphpad Prism, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc09656735-293-9-19?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    ic 50 of the inhibitory concentration calculated using graphpad prism - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier
    four-parameter ic 50 equation using graphpad prism 9  (GraphPad Software Inc)
    90
    GraphPad Software Inc four-parameter ic 50 equation using graphpad prism 9
    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of <t>sacituzumab</t> (anti-TROP2 antibody) or sacituzumab <t>govitecan</t> (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.
    Four Parameter Ic 50 Equation Using Graphpad Prism 9, supplied by GraphPad Software Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
    https://www.bioz.com/product/graphpad+prism+50/pmc09533647-118-18-18?v=GraphPad+Software+Inc
    Average 90 stars, based on 1 article reviews
    four-parameter ic 50 equation using graphpad prism 9 - by Bioz Stars, 2026-06
    90/100 stars
    		  Buy from Supplier

    Image Search Results


    Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.

    Journal: Scientific Reports

    Article Title: A multicenter study on TROP2 as a potential targeted therapy for extramammary Paget disease in Japan

    doi: 10.1038/s41598-024-84566-y

    Figure Lengend Snippet: Effect of TROP2-targeted ADC on proliferation of KS-EMPD-1 cells. KS-EMPD-1 cells were treated with vehicle control (PBS) or various concentrations (0.1–100 μM) of sacituzumab (anti-TROP2 antibody) or sacituzumab govitecan (TROP2-targeted ADC) for 48 h. Then, viable cells were quantified using CCK-8 solution. Experiments were performed in triplicate wells and independently repeated three times. Mean ± SD of fold change of viable cells is shown. *** p < 0.001.

    Article Snippet: IC 50 of sacituzumab govitecan was calculated with GraphPad Prism 7 software (GraphPad Software, San Diego, CA).

    Techniques: Control, CCK-8 Assay